These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Sumatriptan challenge in bipolar patients with and without migraine: a neuroendocrine study of 5-HT1D receptor function. Mahmood T; Silverstone T; Connor R; Herbison P Int Clin Psychopharmacol; 2002 Jan; 17(1):33-6. PubMed ID: 11800504 [TBL] [Abstract][Full Text] [Related]
8. The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. Facchinetti F; Nappi RE; Sances G; Fioroni L; Nappi G; Genazzani AR Clin Endocrinol (Oxf); 1994 Feb; 40(2):211-4. PubMed ID: 8137520 [TBL] [Abstract][Full Text] [Related]
9. Decreased sensitivity of 5-HT1D receptors in chronic tension-type headache. Rainero I; Valfrè W; Savi L; Ferrero M; Del Rizzo P; Limone P; Isaia GC; Gianotti L; Pollo A; Verde R; Benedetti F; Pinessi L Headache; 2002 Sep; 42(8):709-14. PubMed ID: 12390633 [TBL] [Abstract][Full Text] [Related]
10. The effects of gepirone on neuroendocrine function and temperature in humans. Anderson IM; Cowen PJ; Grahame-Smith DG Psychopharmacology (Berl); 1990; 100(4):498-503. PubMed ID: 2157231 [TBL] [Abstract][Full Text] [Related]
13. Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Cuttica CM; Sessarego P; Valenti S; Falivene MR; Giusti M; Giordano G Minerva Endocrinol; 1995 Jun; 20(2):141-4. PubMed ID: 8531896 [TBL] [Abstract][Full Text] [Related]
14. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. Pallanti S; Bernardi S; Allen A; Hollander E J Psychopharmacol; 2010 Dec; 24(12):1802-9. PubMed ID: 19825906 [TBL] [Abstract][Full Text] [Related]
15. The effects of oral sumatriptan, a 5-HT1 receptor agonist, on circulating ACTH and cortisol concentrations in man. Entwisle SJ; Fowler PA; Thomas M; Eckland DJ; Lettis S; York M; Freedman PS Br J Clin Pharmacol; 1995 Apr; 39(4):389-95. PubMed ID: 7640145 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Longmore J; Maguire JJ; MacLeod A; Street L; Schofield WN; Hill RG Br J Clin Pharmacol; 2000 Feb; 49(2):126-31. PubMed ID: 10671906 [TBL] [Abstract][Full Text] [Related]
17. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Pian KL; Westenberg HG; van Megen HJ; den Boer JA Psychopharmacology (Berl); 1998 Dec; 140(3):365-70. PubMed ID: 9877016 [TBL] [Abstract][Full Text] [Related]
18. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Riedel WJ; Klaassen T; Griez E; Honig A; Menheere PP; van Praag HM Neuropsychopharmacology; 2002 Mar; 26(3):358-67. PubMed ID: 11850150 [TBL] [Abstract][Full Text] [Related]
19. Lithium and 5-HT1A receptor sensitivity: a neuroendocrine study in healthy volunteers. Walsh AE; Ware CJ; Cowen PJ Psychopharmacology (Berl); 1991; 105(4):568-72. PubMed ID: 1663254 [TBL] [Abstract][Full Text] [Related]
20. Effects of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients. Pinessi L; Rainero I; Savi L; Valfrè W; Limone P; Calvelli P; Del Rizzo P; Gianotti L; Taliano M; Ghigo E; Arvat E Cephalalgia; 2000 May; 20(4):223-7. PubMed ID: 10999671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]